Gain Therapeutics, Inc. (GANX)
SEC filings, insider trading & institutional ownership from EDGAR.
Couldn’t find the data you were looking for?
We haven’t added Gain Therapeutics, Inc.’s filings yet. We add companies and filings all the time.
Track GANX and we’ll email you the moment its filings are in, free and with no account. Or create a free account to request coverage.
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
No filings are available yet.
Top holders
13F & 13D/G • latest quarter
| Holder | Filed | Value |
|---|---|---|
| DME Capital Management, LP | Aug 14, 2026 | $1.15M |
| Vanguard Capital Management | Aug 13, 2026 | $974.9K |
| GEODE CAPITAL MANAGEMENT, LLC | Aug 12, 2026 | $921.4K |
| BlackRock, Inc. | Aug 7, 2026 | $558.2K |
| UBS Group AG | Aug 13, 2026 | $436.5K |
GANX's filings are public. The insight is one click away.
Scrutar's AI reads every GANX filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Never miss a GANX filing.
Get an email when GANX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Oct 16, 2026Source: SEC EDGAR.